{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:51:25Z","timestamp":1790999485134,"version":"4.1.0"},"reference-count":31,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.3111\/13696998.2013.804411","type":"journal-article","created":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T09:04:57Z","timestamp":1368176697000},"page":"917-925","source":"Crossref","is-referenced-by-count":40,"title":["Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia"],"prefix":"10.3111","volume":"16","author":[{"given":"John M.","family":"Kane","sequence":"first","affiliation":[{"name":"Department of Psychiatry, The Zucker Hillside Hospital and the Hofstra North Shore-LIJ School of Medicine","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Global Clinical Development (CNS), Otsuka Pharmaceutical Development & Commercialization, Inc.","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Biostatistics, Otsuka Pharmaceutical Development & Commercialization, Inc.","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna R.","family":"Duca","sequence":"additional","affiliation":[{"name":"Clinical Management, Otsuka Pharmaceutical Development & Commercialization, Inc.","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Clinical Management, Otsuka Pharmaceutical Development & Commercialization, Inc.","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"McQuade","sequence":"additional","affiliation":[{"name":"Global Medical, Regulatory Affairs and Alliances, Otsuka Pharmaceutical Development & Commercialization, Inc.","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Eramo","sequence":"additional","affiliation":[{"name":"Medical Affairs & Phase IV Clinical Affairs","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Baker","sequence":"additional","affiliation":[{"name":"CNS Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc.","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Peters-Strickland","sequence":"additional","affiliation":[{"name":"Global Clinical Development (CNS), Otsuka Pharmaceutical Development & Commercialization, Inc.","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2013,5,28]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/475027a"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2011.08.008"},{"key":"e_1_3_3_4_1","unstructured":"World Health Organization. WHO. http:\/\/www.who.int\/mental_health\/management\/schizophrenia\/en. Accessed 2012"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0016-5"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0906"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2009.05.004"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.55.8.886"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/21.3.419"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbm061"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.03.031"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.11.020"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10081224"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"De Berardis D Marini S Carano A et al. Efficacy and safety of long acting injectable atypical antipsychotics: a review. Current Clin Pharmacol 2013:[Epub ahead of print]","DOI":"10.2174\/15748847113089990056"},{"key":"e_1_3_3_15_1","unstructured":"FDA. Drugs@FDA. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07530"},{"key":"e_1_3_3_17_1","unstructured":"Otsuka America Pharmaceuticals Inc. Abilify Maintena Prescribing Information. 2013. http:\/\/www.otsuka-us.com\/Products\/Documents\/Abilify.M.PI.pdf"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.771641"},{"key":"e_1_3_3_20_1","article-title":"Healthcare cost reductions associated with the use of lai formulations of antipsychotic medications versus oral among patients with schizophrenia","author":"Lin J","year":"2013","unstructured":"Lin J, Wong B, Offord S, et al. Healthcare cost reductions associated with the use of lai formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Rers 2013. [Epub ahead of print]","journal-title":"J Behav Health Serv Rers"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523001-00004"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523001-00007"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00148365-200806010-00004"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.195.52.s20"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/791468"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/11537680-000000000-00000"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/13651500903311821"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696990903303902"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S16061"},{"key":"e_1_3_3_30_1","unstructured":"Kishimoto T Robenzadeh A Leucht C et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull [Epub ahead of print]"},{"key":"e_1_3_3_31_1","unstructured":"Fleischhacker WW Sanchez R Perry PP et al. Aripiprazole once-monthly for the treatment of schizophrenia: a double-blind randomized non-inferiority study vs. oral aripiprazole. 51st Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 2-6 December 2012; Hollywood FL"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.12.2090"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3111\/13696998.2013.804411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T19:22:59Z","timestamp":1770405779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3111\/13696998.2013.804411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,28]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.3111\/13696998.2013.804411"],"URL":"https:\/\/doi.org\/10.3111\/13696998.2013.804411","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,28]]}}}